Plain-English translation of NCT07326111 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether tirzepatide—a medication originally developed for blood sugar and weight management—can help restore regular menstrual cycles and improve egg release in women with polycystic ovary syndrome (PCOS) who are overweight or obese. Researchers want to see if this medication, given as a weekly injection, can help women with PCOS experience more regular periods and better reproductive health. The study will compare the medication to a placebo (a dummy injection) over 72 weeks.
Women with PCOS often struggle with irregular or missing periods, which can make it harder to get pregnant and affects their overall health. Current treatments don't work well for everyone, so doctors are looking for new options to help restore normal menstrual cycles and improve fertility in women with PCOS.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will visit a research clinic in Germany about 5 times over 72 weeks (about 18 months). You will either receive tirzepatide or a placebo injection once a week that you inject yourself at home into your belly. During the first 20 weeks, the dose will gradually increase to find the right amount for you. You will also be asked to follow a reduced-calorie diet and increase your physical activity. The study team will check your blood, ask about your menstrual cycles, and monitor how you're doing throughout the trial.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Germany